For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Scientific Program

FP119

1666

Dr.Sushma Tejwani
Membership No Author Name Email Mobile
4199N Dr.Pratibha Shanmugam prativim1990@gmail.com 9841236521
Glaucoma

1Yr Clinical Outcomes of iStent inject in Poag: A Real-World Single-Surgeon Experience

Purpose: To evaluate the 1-year efficacy and safety of iStent for reducing IOP and medication burden in mild to moderate POAG. Methods: Retrospective case series of 44 eyes with iStent implantation. IOP, antiglaucoma medications (AGMs), visual fields, and OCT parameters were assessed at baseline and up to 12 months. Analysis was done with paired-samples t-test. Results: Mean baseline IOP was 13.55 ± 2.68 mmHg with 1.74 ± 0.93 AGMs. Postoperatively, IOP was 14.47 ± 3.19 mmHg at 1 month and 13.2 ± 2.38 mmHg at 3 months with 0.02 AGMs (p=0.49). At 12 months, only one patient required AGM. Visual Field index (VFI) on perimetry (p=0.67) and Retinal Nerve fibre layer thickness parameters on OCT (p=0.36) were stable at 1-year. No vision-threatening complications, endothelial cell loss, or hypotony were observed. Conclusions: iStent inject provides sustained IOP control, reduces medication dependence, and demonstrates an excellent safety profile, making it an effective MIGS option for POAG.

Membership No Author Name Email Mobile
4199N Dr.Pratibha Shanmugam prativim1990@gmail.com 9841236521